Virus vaccines: proteins prefer prolines.

Virus vaccines: proteins prefer prolines.
复制标题

DOI:
10.1016/j.chom.2021.02.002
复制
发表时间:
2021-03-10
影响因子:
30.3
通讯作者:
Moore JP
Moore JP
中科院分区:
医学1区
文献类型:
--
作者:
Sanders RW;Moore JP

文献摘要

参考文献

被引文献

相似文献

Most viral vaccines are based on inducing neutralizing antibodies (NAbs) against the virus envelope or spike glycoproteins. Many viral surface proteins exist as trimers that transition from a pre-fusion state when key NAb epitopes are exposed to a post-fusion form in which the potential for virus-cell fusion no longer exists. For optimal vaccine performance, these viral proteins are often engineered to enhance stability and presentation of these NAb epitopes. The method involves the structure-guided introduction of proline residues at key positions that maintain the trimer in the pre-fusion configuration. We review how this technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2. The rapid development of spike protein-based COVID-19 vaccines was facilitated by various lessons learned over the past 20 years. Sanders and Moore review a method devised for HIV-1 vaccine development that was utilized in most COVID-19 vaccines: the stabilization of the spike protein by appropriately positioned proline amino acid substitutions.
DOI: 10.1038/ncomms9143
发表时间: 2015-09-03
影响因子: 16.6
作者:
Krarup A;Truan D;Furmanova-Hollenstein P;Bogaert L;Bouchier P;Bisschop IJM;Widjojoatmodjo MN;Zahn R;Schuitemaker H;McLellan JS;Langedijk JPM
通讯作者: Langedijk JPM
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI: 10.1056/nejmoa2034577
发表时间: 2020-12-31
期刊: The New England journal of medicine
影响因子: --
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者: C4591001 Clinical Trial Group
DOI: 10.1016/j.coviro.2017.03.012
发表时间: 2017-04
影响因子: 5.9
作者:
Graham BS
通讯作者: Graham BS
DOI: 10.1111/imr.12481
发表时间: 2017-01
影响因子: 8.7
作者:
Sanders RW;Moore JP
通讯作者: Moore JP
DOI: 10.1038/s41467-017-01708-9
发表时间: 2017-11-16
影响因子: 16.6
作者:
Battles, Michael B.;Mas, Vicente;McLellan, Jason S.
通讯作者: McLellan, Jason S.